7 Data Trends Reshaping Your Next Pharmacy Benefits Decision

The “2026 State of Pharmacy Benefits Decisions: The Churn Trap” report examines the multiple trends changing how employers approach pharmacy benefits decisions. Based on a survey of 601 employers and 300 benefits advisors conducted by FTI Consulting on behalf of RxBenefits, the report explores what is driving today’s unsettled market — from rising costs and compensation transparency to specialty drug management and GLP-1 oversight. 

Three out of four employers have changed their pharmacy benefits advisor in the past 12 months or expect to within the next 12 months. Many are switching pharmacy benefits managers (PBMs), too. The pressure behind those moves is real. However, the data report explores why switching won’t fix what’s driving the churn.  

Before your next pharmacy benefits decision, see what employers now expect from their partners: transparency as a given, proof that clinical management controls specialty drug trend, and a GLP-1 strategy that holds up on its own. The data shows that active management, not another vendor swap, is what delivers results.